Search
for

    Sort by

    Research 121–150 of 775

    1. Two cases of alopecia areata treated with ruxolitinib: a discussion of ideal dosing and laboratory monitoring International Journal of Dermatology · 2017 · 25 citations
    2. Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib ACG Case Reports Journal · 2021 · 2 citations
    3. Tofacitinib Treatment in Patients With Active COVID-19 Infection Curēus · 2021 · 2 citations
    4. Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient Journal of Allergy and Clinical Immunology Global · 2024 · 5 citations
    5. Efficacy of Upadacitinib in Treating Alopecia Areata, Atopic Dermatitis, and Th1 Comorbidities in Pediatric Patients: A Comprehensive Case Series and Literature Review Journal of Clinical Medicine · 2025 · 2 citations
    6. Oral abrocitinib for treatment of refractory alopecia areata: A retrospective study Journal of the American Academy of Dermatology · 2024 · 4 citations
    7. Upadacitinib for management of recalcitrant alopecia areata: A retrospective case series JAAD case reports · 2023 · 3 citations
    8. 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata Journal of the American Academy of Dermatology · 2024 · 2 citations
    9. Upadacitinib: A New Weapon for the Treatment of Twenty-Nail Dystrophy Indian Journal of Dermatology · 2026
    10. Management of comorbid Crohn's disease and alopecia universalis with upadacitinib and oral minoxidil. PubMed · 2025
    11. Successful treatment of severe diffuse alopecia areata with abrocitinib Anais Brasileiros de Dermatologia · 2025
    12. The Role of Interferon-γ in Autoimmune Polyendocrine Syndrome Type 1 New England Journal of Medicine · 2024 · 71 citations
    13. Sudden improvement of alopecia universalis and psoriatic arthritis while receiving upadacitinib: a case-based review Reumatismo · 2024 · 5 citations
    14. Baricitinib: A Review in Severe Alopecia Areata American Journal of Clinical Dermatology · 2023 · 1 citations
    15. Upadacitinib for the Treatment of Systemic Immune Co-Morbidity in One Case: Alopecia Areata, Vitiligo, Ankylosing Spondylitis, and Allergic Rhinitis-Asthma – Multifaceted Control Clinical Cosmetic and Investigational Dermatology · 2026
    16. Significant improvement with ivarmacitinib after suboptimal response to tofacitinib in severe alopecia areata: a case report and literature review Frontiers in Immunology · 2026
    17. 802 Molecular effect of brepocitinib in hidradenitis suppurativa (HS) Journal of Investigative Dermatology · 2024
    18. Effective treatment of refractory alopecia areata in pediatric patients with oral abrocitinib Journal of cosmetic dermatology · 2023 · 3 citations
    19. 0975 Single-cell transcriptomic profiling reveals distinct immunopathogenic programs in alopecia totalis/universalis compared to patchy alopecia areata Journal of Investigative Dermatology · 2026
    20. Successful treatment of alopecia universalis with abrocitinib: a case report Journal of Dermatological Treatment · 2023 · 19 citations
    21. Ivarmacitinib stimulates hair regrowth in severe alopecia areata 2025
    22. 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata Journal of the American Academy of Dermatology · 2023
    23. Spotlight in Plastic Surgery: October 2022 Plastic and Reconstructive Surgery · 2022
    24. Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy JDDG Journal der Deutschen Dermatologischen Gesellschaft · 2024
    25. Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1) Journal of the American Academy of Dermatology · 2024 · 63 citations
    26. 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata 2019
    27. A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo Journal of The American Academy of Dermatology · 2019 · 25 citations
    28. TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris 2026
    29. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata JCI insight · 2016 · 222 citations
    30. A new era for alopecia areata: New treatments and improved knowledge of the condition 2024 · 1 citations